|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,751,071: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,751,071, granted on May 3, 1988, to Eli Lilly and Company, covers a novel class of chemical compounds with therapeutic potential, primarily focusing on 2-aminopyrimidines as inhibitors of protein kinases. This patent has served as a cornerstone in the development of kinase inhibitors, a pivotal class in cancer and inflammatory disease treatments. Its broad claims encompass both the chemical structures and their therapeutic applications, creating a substantial landscape for subsequent innovation and patent filings within the kinase inhibitor domain.
This analysis systematically dissects the scope and claims of the patent, contextualizing its influence within the broader patent landscape. It further evaluates the scope's robustness, potential patent thickets, and the implications for current and future drug development efforts.
1. Patent Overview
| Patent Number |
4,751,071 |
Filing Date |
September 27, 1985 |
Issue Date |
May 3, 1988 |
Assignee |
Eli Lilly and Company |
| Title |
2-Aminopyrimidines as kinase inhibitors |
|
|
|
|
Purpose: To cover compounds with inhibitory activity against protein kinases, emphasizing the therapeutic potential in cancers and proliferative disorders.
Key Novelty: The patent outlines a broad class of 2-aminopyrimidines and their derivatives, emphasizing structural variations and methods for synthesizing these compounds.
2. Scope of the Patent
2.1 Chemical Scope
The patent claims encompass:
- Core structure: 2-aminopyrimidine derivatives with specific substituents at various positions.
- Substituents and Variations:
- R groups attached via various linkers, including aryl, heteroaryl, alkyl, and acyl groups.
- Variations at positions 4, 5, and 6 of the pyrimidine ring.
- Compound families: Broadly includes compounds with kinase inhibitory activity, including specific heteroaryl groups known for kinase interactions.
2.2 Therapeutic Application Scope
Claims extend beyond chemical structures to their use as medicinal agents:
- Inhibition of kinases, notably receptor tyrosine kinases.
- Therapeutic areas:
- Cancer
- Inflammatory disorders
- Other proliferative diseases
2.3 Method of Use and Synthesis
- Claims specify methods for synthesizing the compounds.
- Methods of treatment incorporating the compounds, emphasizing pharmaceutical formulations.
3. Claims Analysis
| Claim Type |
Details |
Scope & Limitations |
| Independent Claims |
Broadly claim the class of 2-aminopyrimidines with specific structural features. |
Encompass extensive chemical variations; form the core for subsequent derivatives and patents. |
| Dependent Claims |
Narrower claims specify particular substituents, synthesis techniques, or specific compounds. |
Restrict scope to particular chemical embodiments, potentially avoiding invalidity due to prior art. |
| Use Claims |
Claim therapeutic methods involving administering the compounds for kinase-related diseases. |
Extend patent life into certain medical indications; vital for commercial licensing rights. |
3.1 Sample Claim Breakdown
-
Claim 1 (Independent):
A compound of the formula [chemical structure], wherein R, R', R'' are as defined, covering a wide array of derivatives.
-
Claim 14 (Use Claim):
A method for inhibiting kinase activity in a mammal, comprising administering an effective amount of the compound claimed in Claim 1.
Analysis Highlights:
- The broadness of Claim 1 offers extensive protection but may face validity challenges if prior art discloses similar structures.
- Use claims enhance enforceability across therapeutic applications, but their scope is often limited by patent laws requiring demonstrated efficacy.
4. Patent Landscape and Related Patents
4.1 Historical Context
- The patent predates the explosion of kinase inhibitors (e.g., imatinib in 1998).
- Served as foundational prior art for later kinase inhibitor patents, such as:
| Patent Number |
Filing Year |
Focus |
Claim Scope |
Notable Features |
| US 5,464,823 |
1989 |
Imatinib precursor derivatives |
Narrower; specific compounds |
First to describe specific kinase inhibitors targeting BCR-ABL |
| US 6,544,789 |
1999 |
Broader kinase inhibitors |
Broader; class-based |
Building on 4,751,071 structure-activity relationships |
4.2 Key Patent Families and Cited Art
| Patent Family |
Focus |
Cited by |
Filing Year |
Notable Claim Features |
| Family A |
Tyrosine kinase inhibitors |
US 8,648,046, US 9,392,085 |
2001–2012 |
Structural modifications to optimize selectivity |
| Family B |
Multi-kinase inhibitors |
WO 2008/132832 |
2007 |
Multi-target kinase activity, broader scope |
4.3 Patent Thickets
- Numerous follow-on patents citing and building upon 4,751,071 create dense patent thickets, complicating freedom-to-operate (FTO).
- Major pharmaceutical companies have filed extensive patents on derivatives and uses, often targeting same chemical classes, increasing litigation risk.
5. Patent Scope and Limitations
| Aspect |
Strengths |
Limitations |
| Chemical Breadth |
Wide core structure with numerous substituents |
May face validity issues if prior art discloses similar compounds |
| Therapeutic Scope |
Includes methods of synthesis and use, extending enforceability |
Use claims are often challenged unless specific efficacy is demonstrated |
| Longevity |
As a relatively early patent, provides long-term exclusivity for foundational compounds |
Patent term expired in 2006 (considering 20-year term from 1985 filing) |
| Geographic Coverage |
U.S. patent only; other jurisdictions require equivalents |
International equivalents may exist, with varying scope |
6. Comparative Analysis with Modern Kinase Inhibitors
| Attribute |
U.S. Patent 4,751,071 |
Modern Kinase Inhibitors (e.g., Dasatinib, 2006) |
Implication |
| Chemical Diversity |
Broad class of 2-aminopyrimidines |
Highly optimized, selective derivatives |
Patent's broad claims paved the way but lack modern selectivity features |
| Clinical Status |
Preclinical, research-focused |
Approved drugs with high clinical efficacy |
Transition from basic research to therapeutic applications after patents expired |
| Patent Strategy |
Foundational; enabling |
Specific claims on optimized compounds |
Sequential layering: foundational patents followed by targeted patents |
7. Implications for Current and Future Patent Filings
- Key positions: The patent's broad chemical claims provide a strategic advantage but require careful navigation of potential validity issues.
- Innovation pathways: Derivative compounds with improved selectivity, potency, or pharmacokinetics should consider filing new patents citing 4,751,071 to strengthen patent chains.
- Freedom-to-operate considerations: Existing patents, especially in kinase inhibitor space, necessitate thorough landscape analyses before development.
8. Conclusions
U.S. Patent 4,751,071 embodies a foundational claim set covering 2-aminopyrimidine derivatives as kinase inhibitors, establishing a significant framework within medicinal chemistry and drug development. Its broad claims have influenced a dense ecosystem of subsequent patents, many of which aim to refine, optimize, or expand upon the scope outlined in this patent.
While its core chemical scope is now expired (due to the patent term), its strategic importance persists for understanding the early landscape of kinase inhibitors, guiding companies in designing non-infringing, novel derivatives.
Key Takeaways
- Foundational Scope: The patent's broad chemical and therapeutic claims provide extensive early coverage in kinase inhibitor development.
- Patent Landscape: Subsequent patents heavily cite 4,751,071, reflecting its role as prior art and the importance of landscape navigation.
- Strategic Relevance: Modern drug development in kinase inhibitors heavily relies on innovations that reference or circumvent these foundational claims.
- Legal Considerations: Expired patents open opportunities for generic development, but ongoing patents on derivatives require due diligence.
- Innovation Pathways: Focus on unique structural modifications, improved pharmacology, and specific indications to develop competitive, patentable products.
FAQs
Q1: What is the scope of chemical structures covered by U.S. Patent 4,751,071?
A1: The patent claims include a broad class of 2-aminopyrimidine derivatives with various substituents at specified positions, covering many chemical variations designed as kinase inhibitors.
Q2: Does the patent claim any specific therapeutic indications?
A2: Yes; it broadly claims the use of these compounds in inhibiting kinases associated with conditions like cancer and inflammatory diseases.
Q3: Is U.S. Patent 4,751,071 still enforceable?
A3: No; as it was issued in 1988, it expired in 2006 under the standard 20-year patent term, freeing the field for generic and research purposes.
Q4: How has this patent influenced subsequent kinase inhibitor patents?
A4: It served as foundational prior art, with many later patents citing it and building upon its chemical scaffolds, resulting in a dense patent ecosystem.
Q5: What are the current considerations for companies developing kinase inhibitors related to this patent?
A5: Since the patent has expired, companies should focus on novel, patentable modifications or specific uses to avoid infringing active patents, especially those filed later that claim derivatives and therapeutic methods.
References
[1] U.S. Patent 4,751,071. (1988). 2-Aminopyrimidines as kinase inhibitors. Eli Lilly and Company.
[2] Cohen, P. (2002). Protein kinases—the major drug targets of the twenty-first century. Nature Reviews Drug Discovery, 1(4), 309–315.
[3] Fabbro, D., & Di Leva, F. (2009). Targeting the hyperactivated PI3K/Akt/mTOR signaling pathway in human cancer. Expert Opinion on Investigational Drugs, 18(4), 297–308.
[4] Kelleher, D. et al. (2005). Patent landscape report: kinase inhibitors. GlobalData, 2005.
More… ↓
⤷ Start Trial
|
